Homocysteine and stroke: Evidence on a causal link from mendelian randomisation

Lancet

Volumn 365, Issue 9455, 2005, Pages 224-232

  Casas, Juan P ^a   Bautista, Leonelo E ^b   Smeeth, Liam ^c   Sharma, Pankaj ^d   Hingorani, Aroon D ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; EMBASE; ETHNIC DIFFERENCE; GENE INTERACTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; GEOGRAPHIC DISTRIBUTION; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MEDLINE; META ANALYSIS; PATHOGENICITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CONTENT; RANDOMIZATION; STROKE;

EID: 12344309062     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)70152-5     Document Type: Article

References (34)

1. WHO. The World Health Report 2002: reducing risks, promoting healthy life. Geneva: WHO, 2002. Also available at http://www.who.int/whr/2002/en/ (accessed Oct 4, 2003).
2. Warlow CP. Epidemiology of stroke. Lancet. 352:(suppl 3):1998;SIII1-4
3. Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation. 103:2001;163-182
4. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 325:2002;1202-1206
5. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 288:2002;2015-2022
6. Bautista LE, Arenas IA, Penuela A, Martinez LX. Total plasma homocysteine level and risk of cardiovascular disease: a meta-analysis of prospective cohort studies. J Clin Epidemiol. 55:2002;882-887
7. Brattstrom L, Wilcken DE. Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr. 72:2000;315-323
8. Ueland PM, Refsum H, Beresford SAA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr. 72:2000;324-332
9. Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 288:2002;2023-2031
10. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation. 98:1998;2520-2526
11. Morgan TH. Heredity and sex. 1913;Columbia University Press, New York
12. Smith GD, Ebrahim S. Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 32:2003;1-22
13. Smith GD, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol. 33:2004;30-42
14. Clarke R, Armitage J. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements. Semin Thromb Hemost. 26:2000;341-348
15. Kelly PJ, Rosand J, Kistler JP, et al. Homocysteine, MTHFR 677C→T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology. 59:2002;529-536
16. Casas JP, Hingorani AD, Bautista LE, Sharma P. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch Neurol. 61:2004;1652-1661
17. DerSimonian R, Laird NM. Meta-analysis in clinical trials. Control Clin Trials. 7:1986;177-188
18. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 22:1959;719-748
19. Robin JS, Greenland S, Breslow NE. A general estimator of the variance of the Mantel-Haenszel odds ratio. Am J Epidemiol. 124:1986;719-723
20. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in a meta-analysis. Egger M, Davey Smith G, Altman DG. Systematic reviews in health care: meta-analysis in context. 2001;285-312 BMJ Publications, London
21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:1997;629-634
22. Lau J, Ioannidis JPA, Schmid CH. Summing up evidence: one answer is not always enough. Lancet. 351:1998;123-127
23. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 326:2003;219
24. Keavney BD, Youngman LD, Palmer A, et al. Large-scale test of hypothesized associations between polymorphisms of lipid-related genes and myocardial infarction in about 5000 cases and 6000 controls. Circulation 2000; 102 (suppl II): 852 (abstr).
25. Youngman LD, Keavney BD, Palmer A, et al. Plasma fibrinogen and fibrinogen genotypes in 4865 cases of myocardial infarction and 6002 controls: test of causality by "Mendelian randomization". Circulation 2000; 102 (suppl II): 32 (abstr).
26. Wald DS, Bishop L, Wald NJ, et al. Randomized trial of folic acid supplementation and serum homocysteine levels. Arch Intern Med. 161:2001;695-700
27. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study - a randomized controlled trial. JAMA. 288:2002;973-979
28. VITATOPS Trial Study Group. The VITATOPS (Vitamins to Prevent Stroke) Trial: rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke. Cerebrovasc Dis. 13:2002;120-126
29. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 291:2004;565-575
30. Russo GT, Friso S, Jacques PF, et al. Age and gender affect the relation between methylenetetrahydrofolate reductase C677T genotype and fasting plasma homocysteine concentrations in the Framingham Offspring Study Cohort. J Nutr. 133:2003;3416-3421
31. Keavney B. Genetic epidemiological studies of coronary heart disease. Int J Epidemiol. 31:2002;730-736
32. Clayton D, McKeigue PM. Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet. 358:2001;1356-1360
33. Little J, Khoury MJ. Mendelian randomisation: a new spin or real progress? Lancet. 362:2003;930-931
34. Nallamothu BK, Fendrick AM, Rubenfire M, Saint S, Bandekar RR, Omenn GS. Potential clinical and economic effects of homocyst(e)ine lowering. Arch Intern Med. 160:2000;3406-3412